This clinical trial is focused on studying a condition known as Refractory Status Epilepticus (RSE). RSE is a severe form of seizure that does not respond to standard treatments. The study is testing a medication called Ganaxolone, which is given through an intravenous (IV) method, meaning it is administered directly into the bloodstream. Ganaxolone is being tested to see if it can help stop seizures when added to the usual care that patients with RSE receive.

The purpose of the study is to evaluate how effective, safe, and tolerable Ganaxolone is when used alongside standard treatments for RSE. Participants in the study will receive either Ganaxolone or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving Ganaxolone and who is receiving the placebo, to ensure unbiased results.

Throughout the study, participants will be closely monitored to see if their seizures stop within a short time after starting the treatment and to check if there is a need for additional treatments. The study will also look at the safety of Ganaxolone by observing any side effects that may occur. The trial aims to provide valuable information on whether Ganaxolone can be a beneficial addition to the treatment options for people with RSE.